These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32172494)

  • 1. The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.
    Dintsios CM; Beinhauer I
    Health Econ Rev; 2020 Mar; 10(1):7. PubMed ID: 32172494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical Pricing in Germany: How Is Value Determined within the Scope of AMNOG?
    Lauenroth VD; Stargardt T
    Value Health; 2017; 20(7):927-935. PubMed ID: 28712622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of Orphan Drug Prices in Germany.
    Worm F; Dintsios CM
    Pharmacoeconomics; 2020 Apr; 38(4):397-411. PubMed ID: 31903523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of negotiated prices for new drugs in Germany.
    Gandjour A; Schüßler S; Hammerschmidt T; Dintsios CM
    Eur J Health Econ; 2020 Sep; 21(7):1049-1057. PubMed ID: 32451745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit assessment in Germany: implications for price discounts.
    Theidel U; von der Schulenburg JM
    Health Econ Rev; 2016 Dec; 6(1):33. PubMed ID: 27485438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit.
    Kleining K; Laufenberg J; Thrun P; Ehlert D; Wasem J; Bartol A
    Health Econ Policy Law; 2024 Apr; 19(2):216-233. PubMed ID: 37577932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefit Assessment and Price Negotiation Under AMNOG: Calculable Process or Unfair Poker Game?].
    Radic D; Haugk S; Radic M
    Gesundheitswesen; 2018 Jun; 80(6):573-579. PubMed ID: 27636366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
    Wettstein DJ; Boes S
    BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of early benefit assessment of ophthalmic drugs in Germany: success story or not?
    Dintsios CM
    Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):283-297. PubMed ID: 33999735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Price increase negotiations to address drug shortages in South Korea's national health insurance.
    Yu SR; Lee JH
    Front Pharmacol; 2023; 14():1307462. PubMed ID: 38111380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact Of Price Regulation On The Availability Of New Drugs In Germany.
    Stern AD; Pietrulla F; Herr A; Kesselheim AS; Sarpatwari A
    Health Aff (Millwood); 2019 Jul; 38(7):1182-1187. PubMed ID: 31260362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. German Pharmaceutical Pricing: Lessons for the United States.
    Rodwin MA; Gerke S
    Int J Health Serv; 2022 Jan; 52(1):146-158. PubMed ID: 34668806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Policy in the Czech Republic.
    Skoupá J
    Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.